Companies › PAQ Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PT0253 KRAS G12D inhibitor | KRAS | Phase 1 | Solid Tumor | Dec 2026 |
| PT0511 KRAS inhibitor | KRAS | Phase 1 | Colorectal Cancer | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06797336 | PT0253 | Phase 1 | Solid Tumor | Oncology | Dec 2026 |
| NCT07300150 | PT0511 | Phase 1 | Colorectal Cancer | Oncology | Oct 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.